Two new susceptibility loci 1q24.2 and 11p11.2 confer risk to severe acne
Li He(Kunming Medical University), Ya‐Ping Zhang(Institució Catalana de Recerca i Estudis Avançats), Ting Yang, Jiankang Yang(Shanghai University of Traditional Chinese Medicine), Yijin Huang(First Affiliated Hospital of Xiamen University), Fusheng Zhou(Central South University), Wei Lai(Sun Yat-sen University), Yanping Bai(China-Japan Friendship Hospital), Fengyan Lu(Kunming Medical University), Xing Zheng(Kunming Institute of Zoology), Cui-Lin Ma(Xijing Hospital), Xiao-Yan Yang(Chaozhou Central Hospital), Wenjuan Wu(Shanghai East Hospital), Qianjin Lu(Central South University), Hui Li(China-Japan Friendship Hospital), Qing Sun(Children's Hospital of Pittsburgh), Jue Qi(Kunming Medical University), Huailiang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Liangdan Sun(North China University of Science and Technology), Chunyang Li(Qingdao University), Gang Chen(Tongji Hospital), Meimei Wang(Baotou Medical College), Lin Wang(West China Medical Center of Sichuan University), Weizhen Wang(Hong Kong Polytechnic University), Na Luo(Karlsruhe Institute of Technology), Bo Liang(Anhui Medical University), Zhanchao Zhou(American Academy of Cosmetic Surgery), Hui Cheng(Anhui Medical University), Tianwen Gao(Xijing Hospital), Shengxiang Xiao(Second Affiliated Hospital of Xi'an Jiaotong University), Jianqing Huang(Fuzhou Dermatosis Prevention Hospital), Yeqiang Liu(Tongji University)
Cited by 74
Related Papers
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study
|Chinese Medical Journal|2020|1.4k
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus
|Nature Genetics|2009|951
New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis
|Redox Biology|2018|753
United States Food and Drug Administration Drug Approval Summary
|Clinical Cancer Research|2004|500